TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32817077.
- Also identified by DOI 10.1158/1078-0432.CCR-20-2538.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
IL15 and TIGIT blockade enhances the natural killer (NK) cell-mediated activity against MHC-I-deficient melanoma both <i>in vitro</i> and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8<sup>+</sup> T cell-mediated control.<i>See related article by Chauvin et al., p. 5520</i>.
Medical subject headings
- Interleukin-15
- Melanoma